Cover Image
Market Research Report

Global Neurodegenerative Diseases Therapeutics Market 2018 -2022

Published by TechNavio (Infiniti Research Ltd.) Product code 762875
Published Content info 113 Pages
Delivery time: 1-2 business days
Price
Back to Top
Global Neurodegenerative Diseases Therapeutics Market 2018 -2022
Published: December 17, 2018 Content info: 113 Pages
Description

About this market

Increase in aging population to drive growth in the market. The aging population has been increasing globally with declining fertility and increasing longevity. Medicine has prolonged the morbidity phase, which has, in turn increased the risk of developing neurological disorders such as Alzheimer's and Parkinson's disease. Technavio's analysts have predicted that the neurodegenerative diseases therapeutics market will register a CAGR of almost 8% by 2022.

Market Overview

Availability of highly sensitive diagnostic modalities

The development of advanced diagnostic modalities to identify disease manifestation at its earliest stages facilitates early treatment decisions, thereby easing disease burden. Neuroimaging is one of the methods for the early diagnosis of neurodegenerative diseases.

High failure rate of neurodegenerative drugs in clinical trials

There has been a continuous development of drugs for the treatment of neurodegenerative diseases. However, there is reportedly a high failure rate of neurodegenerative drugs in clinical trials.

For the detailed list of factors that will drive and challenge the growth of the neurodegenerative diseases therapeutics market during the 2018-2022, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Novartis and Teva Pharmaceutical the competitive environment is quite intense. Factors such as the increase in aging population and the availability of highly sensitive diagnostic modalities, will provide considerable growth opportunities to neurodegenerative diseases therapeutics manufactures. ALLERGAN, Biogen, Novartis, and Teva Pharmaceutical are some of the major companies covered in this report.

Table of Contents
Product Code: IRTNTR23810

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE ANALYSIS

  • Pipeline analysis

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY INDICATION

  • Segmentation by indication
  • Comparison by indication
  • Multiple sclerosis - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Alzheimer's disease - Market size and forecast 2017-2022
  • Parkinson's disease - Market size and forecast 2017-2022
  • Huntington's disease - Market size and forecast 2017-2022
  • Market opportunity by indication

PART 09: MARKET SEGMENTATION BY DRUG CLASS

  • Segmentation by drug class

PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity

PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 14: MARKET TRENDS

PART 15: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 16: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • ALLERGAN
  • Biogen
  • Novartis
  • Teva Pharmaceutical

PART 17: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Parent market
  • Exhibit 02: Global CNS therapeutics market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Pipeline drugs under Phase III development
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global neurodegenerative diseases therapeutics market - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 10: Global neurodegenerative diseases therapeutics market - Year over year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global neurodegenerative diseases therapeutics market by indication - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by indication
  • Exhibit 21: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 22: Global neurodegenerative diseases therapeutics market by multiple sclerosis - Year over year growth 2018-2022 (%)
  • Exhibit 23: Global neurodegenerative diseases therapeutics market by others - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 24: Global neurodegenerative diseases therapeutics market by others - Year over year growth 2018-2022 (%)
  • Exhibit 25: Global neurodegenerative diseases therapeutics market by Alzheimer's disease - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 26: Global neurodegenerative diseases therapeutics market by Alzheimer's disease - Year over year growth 2018-2022 (%)
  • Exhibit 27: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 28: Global neurodegenerative diseases therapeutics market by Parkinson's disease - Year over year growth 2018-2022 (%)
  • Exhibit 29: Global neurodegenerative diseases therapeutics market by Huntington's disease - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 30: Global neurodegenerative diseases therapeutics market by Huntington's disease - Year over year growth 2018-2022 (%)
  • Exhibit 31: Market opportunity by indication
  • Exhibit 32: Customer landscape
  • Exhibit 33: Global neurodegenerative diseases therapeutics market by region - Market share 2017-2022 (%)
  • Exhibit 34: Regional comparison
  • Exhibit 35: Neurodegenerative diseases therapeutics market in Americas - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 36: Neurodegenerative diseases therapeutics market in Americas - Year over year growth 2018-2022 (%)
  • Exhibit 37: Top 3 countries in Americas
  • Exhibit 38: Neurodegenerative diseases therapeutics market in EMEA - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 39: Neurodegenerative diseases therapeutics market in EMEA - Year over year growth 2018-2022 (%)
  • Exhibit 40: Top 3 countries in EMEA
  • Exhibit 41: Neurodegenerative diseases therapeutics market in APAC - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 42: Neurodegenerative diseases therapeutics market in APAC - Year over year growth 2018-2022 (%)
  • Exhibit 43: Top 3 countries in APAC
  • Exhibit 44: Market opportunity
  • Exhibit 45: Late-stage pipeline for different neurogenerative diseases during 2017-2018
  • Exhibit 46: Some patent expiries of neurodegenerative diseases in US
  • Exhibit 47: Some drug failures for neurodegenerative diseases in clinical trials in 2017-2018
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: Vendor overview
  • Exhibit 54: ALLERGAN - Business segments
  • Exhibit 55: ALLERGAN - Organizational developments
  • Exhibit 56: ALLERGAN - Geographic focus
  • Exhibit 57: ALLERGAN - Segment focus
  • Exhibit 58: ALLERGAN - Key offerings
  • Exhibit 59: Vendor overview
  • Exhibit 60: Biogen - Business segments
  • Exhibit 61: Biogen - Organizational developments
  • Exhibit 62: Biogen - Geographic focus
  • Exhibit 63: Biogen - Key offerings
  • Exhibit 64: Vendor overview
  • Exhibit 65: Novartis - Business segments
  • Exhibit 66: Novartis - Organizational developments
  • Exhibit 67: Novartis - Geographic focus
  • Exhibit 68: Novartis - Segment focus
  • Exhibit 69: Novartis - Key offerings
  • Exhibit 70: Vendor overview
  • Exhibit 71: Teva Pharmaceutical - Business segments
  • Exhibit 72: Teva Pharmaceutical - Organizational developments
  • Exhibit 73: Teva Pharmaceutical - Geographic focus
  • Exhibit 74: Teva Pharmaceutical - Segment focus
  • Exhibit 75: Teva Pharmaceutical - Key offerings
Back to Top